Successful heart transplantation in a patient who recovered from COVID‐19

Johnstad, Christine; Murray, David R.; Dhingra, Ravi; Smith, Jason W.; Fiedler, Amy G.

doi:10.1111/jocs.15331

Cited by 5 publications

(3 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 19 Previous case reports have demonstrated that patients who had COVID-19 infection prior to undergoing transplantation did not encounter any instances of reinfection, reactivation, or COVID-19-associated complications post-transplantation. 20 21 22 23 24 25 26 In accordance with the aforementioned cases, we did not detect any COVID-19-associated complications following transplantation in our study.…”

supporting

confidence: 90%

Comparison of the Clinical Outcomes Between Early and Delayed Transplantation After SARS-CoV-2 Infection

Ra,

Kim,

Jang

et al. 2024

J Korean Med Sci

View full text Add to dashboard Cite

Our study analyzed 95 solid organ transplant (SOT) and 78 hematopoietic stem cell transplant (HSCT) recipients with prior coronavirus disease 2019 (COVID-19). Patients who underwent transplantation within 30 days of COVID-19 infection comprised the early group, and those who underwent transplantation post-30 days of COVID-19 infection comprised the delayed group. In the early transplantation group, no patient, whether undergoing SOT and HSCT, experienced COVID-19-associated complications. In the delayed transplantation group, one patient each from SOT and HSCT experienced COVID-19-associated complications. Additionally, among early SOT and HSCT recipients, two and six patients underwent transplantation within seven days of COVID-19 diagnosis, respectively. However, no significant differences were observed in the clinical outcomes of these patients compared to those in other patients. Early transplantation following severe acute respiratory syndrome coronavirus 2 infection can be performed without increased risk of COVID-19-associated complications. Therefore, transplantation needs not be delayed by COVID-19 infection.

show abstract

supporting

confidence: 90%

Comparison of the Clinical Outcomes Between Early and Delayed Transplantation After SARS-CoV-2 Infection

Ra,

Kim,

Jang

et al. 2024

J Korean Med Sci

View full text Add to dashboard Cite

show abstract

“…Another complex procedure is a heart transplant in a COVID-19 recovered patient. The first such case was performed in the USA [ 32 ]. In another report, a heart re-transplantation was performed in a patient in the recovery phase of COVID-19 with an RT-PCR positive report.…”

Section: Lung and Heart Transplantation After Recovery From Covid-19mentioning

confidence: 99%

Solid Organ Transplantation in SARS-CoV-2 Recovered Transplant Candidates: a Comprehensive Review of Recent Literature

et al. 2022

View full text Add to dashboard Cite

Purpose of Review As the coronavirus disease 2019 (COVID-19) pandemic continues to surge, determining the safety and timing of proceeding with solid organ transplantation (SOT) in transplant candidates who have recovered from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and who are otherwise transplant eligible is an important concern. We reviewed the current status of protocols and the outcomes of SOT in SARS-CoV-2 recovered patients. Recent Findings We identified 44 published reports up through 7 September 2021, comprising 183 SOT [kidney = 115; lung = 27; liver = 36; heart = 3; simultaneous pancreas-kidney (SPK) = 1, small bowel = 1] transplants in SARS-CoV-2 recovered patients. The majority of these were living donor transplants. A positive SARS-CoV-2 antibody test, although not obligatory in most reports, was a useful tool to strengthen the decision to proceed with transplant. Two consecutive real-time polymerase chain test (RT-PCR) negative tests was one of the main prerequisites for transplant in many reports. However, some reports suggest that life-saving transplantation can proceed in select circumstances without waiting for a negative RT-PCR. In general, the standard immunosuppression regimen was not changed. Summary In select cases, SOT in COVID-19 recovered patients appears successful in short-term follow-up. Emergency SOT can be performed with active SARS-CoV-2 infection in some cases. In general, continuing standard immunosuppression regimen may be reasonable, except in cases of inadvertent transplantation with active SARS-CoV-2. Available reports are predominantly in kidney transplant recipients, and more data for other organ transplants are needed.

show abstract

“…Heart organ donation and transplantation were significantly affected in the United States due to the COVID-19 pandemic. Recipients on the waitlist had an increased risk of acquiring COVID‐19 [ 51 ]. From March 2020 to May 2020, organ authorization and recovery rates fell by 11% and 17%, respectively, as social distancing reduced hospital admissions and traumatic deaths [ 52 ].…”

Section: Reviewmentioning

confidence: 99%

Expanding Selection Criteria to Repairable Diseased Hearts to Meet the Demand of Shortage of Donors in Heart Transplantation

Yazji¹,

Garg²,

Wadiwala³

et al. 2022

Cureus

View full text Add to dashboard Cite

Heart transplant surgery is considered the destination therapy for end-stage heart disease. Unfortunately, many patients in the United States of America who are eligible candidates for transplants cannot undergo surgery due to donor shortage. In addition, some donors' hearts are being labeled as unacceptable for transplant surgery because of the rigorous and restricted rules placed on the approval process of using a donor's heart. Over the last few decades, the rising discrepancy between the scarcity of donor hearts and the demand for such organs has led to the discussion of expanding the donor heart selection criteria. A softer view on using marginal hearts for transplants would help those on the waitlist to receive a heart transplant. Marginal hearts that contain the hepatitis c virus (HCV), COVID-19, older age, or repairable heart defects have become viable options to use for a heart transplant. Also, the prioritization based on the new heart allocation system would help efficiently decide which recipients would be the first to get a donor's heart. Recently there has been a consensus to broaden the eligibility of donor's hearts by accepting valvular abnormalities, coronary artery disease, and congenital abnormalities. This review highlights some of those expansions in selection criteria in particular using repairable hearts, which could be fixed in the operating room on the back table before transplantation.

show abstract

Successful heart transplantation in a patient who recovered from COVID‐19

Cited by 5 publications

References 2 publications

Comparison of the Clinical Outcomes Between Early and Delayed Transplantation After SARS-CoV-2 Infection

Comparison of the Clinical Outcomes Between Early and Delayed Transplantation After SARS-CoV-2 Infection

Solid Organ Transplantation in SARS-CoV-2 Recovered Transplant Candidates: a Comprehensive Review of Recent Literature

Expanding Selection Criteria to Repairable Diseased Hearts to Meet the Demand of Shortage of Donors in Heart Transplantation

Contact Info

Product

Resources

About